ABSI
$2.96-0.12 (-3.90%)
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States.
Recent News
InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates
InflaRx (IFRX) delivered earnings and revenue surprises of +2.86% and -117.03%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Absci Highlights AI Antibody Platform, ABS-201 Hair-Loss Trial Milestones at Leerink Conference
Absci (NASDAQ:ABSI) used a presentation at the Leerink Partners Global Healthcare Conference to outline how the company is applying its internal AI-driven drug design platform to generate “differentiated” antibody assets, while advancing its own lead clinical program, ABS-201, in androgenetic alopec
Absci Conference: Agentic AI Push and ABS-201 Hair-Loss Program Take Center Stage
Executives from Absci (NASDAQ:ABSI) used a conference presentation to emphasize the company’s focus on building clinical-stage drug assets using artificial intelligence, with management repeatedly framing long-term value creation around programs that advance into and through the clinic rather than s
Absci Corporation's (NASDAQ:ABSI) recent 12% pullback adds to one-year year losses, institutional owners may take drastic measures
Key Insights Significantly high institutional ownership implies Absci's stock price is sensitive to their trading...
Absci Unveils Origin-1 AI Model, Teases 2025 Hair-Loss Data and Q4 Endometriosis Trial Launch
Absci (NASDAQ:ABSI) used a presentation at the 44th JPMorgan Healthcare Conference to outline recent platform updates and provide a timeline for upcoming clinical data in androgenic alopecia and endometriosis. Founder and CEO Sean McClain said the company is “entering this really exciting new era” i